Clinical Efficacy and Adverse Reactions of Piperacillin Sodium and Tazobactam Sodium in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Objective To observe the clinical efficacy and adverse reactions of piperacillin sodium and tazobactam sodium in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 60 patients with acute exacerbation of chronic obstructive pulmonary disease diagnosed and treated in our hospital from May 2021 to May 2023 were selected as the research objects.They were divided into control group(n=30)and observation group(n=30)by random number table method.The control group was treated with conventional symptomatic treatment,and the observation group was treated with piperacillin sodium and tazobactam sodium on the basis of the control group.The clinical efficacy,improvement time of clinical symptoms(pulmonary rales,dyspnea,shortness of breath),pulmonary function indexes[peak expiratory flow(PEF),forced expiratory volume in the first second(FEV1),forced vital capacity(FVC)],blood gas indexes[partial pressure of oxygen(PaO2),arterial oxygen saturation(SaO2)]and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.67％,which was higher than 83.33％in the control group(P＜0.05).The improvement time of pulmonary rales,dyspnea and shortness of breath in the observation group was shorter than that in the control group(P＜0.05).After treatment,PEF,FEV1 and FVC in the two groups were higher than those before treatment,and those in the observation group were higher than those in the control group(P＜0.05).After treatment,PaO2 and SaO2 in the two groups were higher than those before treatment,and those in the observation group were higher than those in the control group(P＜0.05).The incidence of adverse reactions in the observation group was 10.00％,which was compared with 6.67％in the control group,the difference was not statistically significant(P＞0.05).Conclusion Piperacillin sodium and tazobactam sodium is effective in the treatment of acute exacerbation of chronic obstructive pulmonary disease,which can shorten the improvement time of pulmonary rales,dyspnea and shortness of breath,improve blood gas index and lung function index,and will not increase the incidence of adverse reactions.
Piperacillin sodium and tazobactam sodiumChronic obstructive pulmonary diseaseAcute exacerbationLung function
万方数据
维普
